Locus Biosciences

Locus Biosciences is a developer of precision antimicrobial therapeutics for infectious diseases and inflammatory conditions. The company has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria, enabling the development of targeted antimicrobials that kill harmful bacteria while preserving beneficial microbiome. This CRISPR-based approach offers an alternative to traditional antibiotics, addressing the growing crisis of antimicrobial resistance. Locus Biosciences' technology programs target urinary tract infections, Clostridioides difficile infections, and other bacterial diseases. Founded in 2015 and headquartered in Raleigh, North Carolina, Locus Biosciences has raised approximately $67.3 million at the Series B stage from investors including Artis Ventures, Viking Global Investors, Tencent, Johnson & Johnson Innovation, Illumina, Hercules Capital, Abstract Ventures, NCBiotech, HHS, Starlight Ventures, TechAccel, and Codon Capital.